Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Exact Sciences (EXAS) today. The company’s shares closed last Monday at $37.90, close to its 52-week low of $35.25.
According to TipRanks.com, DeGeeter is a 1-star analyst with an average return of -6.0% and a 32.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Molecular Templates, and Cidara Therapeutics.
Currently, the analyst consensus on Exact Sciences is a Strong Buy with an average price target of $121.17.
See today’s analyst top recommended stocks >>
Based on Exact Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $77.95 million. In comparison, last year the company had a GAAP net loss of $53.97 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
